Adjuvant interferon therapy for malignant melanoma: the debate.
- Author:
Qiang ZHOU
1
;
Xiao-Shi ZHANG
Author Information
1. State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, PR China.
- Publication Type:Journal Article
- MeSH:
Chemotherapy, Adjuvant;
Disease-Free Survival;
Dose-Response Relationship, Drug;
Humans;
Interferon-alpha;
administration & dosage;
therapeutic use;
Melanoma;
drug therapy;
Polyethylene Glycols;
therapeutic use;
Recombinant Proteins;
administration & dosage;
therapeutic use;
Skin Neoplasms;
drug therapy;
Survival Rate
- From:Chinese Journal of Cancer
2010;29(11):907-913
- CountryChina
- Language:English
-
Abstract:
Based on the results of the Kirkwood high-dose interferon alpha-2b (HDI) adjuvant therapy trial of the Eastern Cooperative Oncology Group 1684, the US Food and Drug Administration (FDA) approved HDI as the postoperative adjuvant therapy for high-risk melanoma. Unfortunately, controversies continue regarding the use of interferon (IFN) as adjuvant therapy for melanoma owing to the inconsistent results of subsequent trials. Numerous trials of adjuvant interferon therapy demonstrated a benefit in terms of relapse-free survival (RFS), but without confirmed significant effect on overall survival (OS). The optimal timing, dose, and type of interferon are not yet defined. Therefore, adjuvant interferon treatment is preferentially applied in the randomized clinical trials in specialized centers. Decisions about the appropriateness of adjuvant interferon alfa-2b treatment for patients should be made on an individual basis, after discussion with the patient, including an explanation of the potential benefits and side effects of interferon therapy. Moreover, we also need to use available regimens reasonably, seek feasible and predictable prognostic factors to serve patients with individualized therapy.
